FSUE “Endopharm” subordinated to the Ministry of Industry and Trade of Russia produces more than 130 titles of medicines in demand in various fields of medicine, 75% of which are included in the vital and essential medicines list.
In the current geopolitical and economic situation, the Enterprise delivers socially significant products to all constituent entities of the Russian Federation. The Enterprise constantly invests in the development and production of science-intensive high-tech products ensuring the availability of demanded medicines for Russian citizens, which is one of the priority tasks of the healthcare system.
In accordance with Decree of the Government of the Russian Federation dd. December 26, 2019 No. 1858 “On the provision of subsidies from the federal budget for capital investments in capital construction projects of the Federal State Unitary Enterprise “Moscow Endocrine Plant”, the Enterprise, together with the Ministry of Industry and Trade of Russia, is implementing the investment project “Construction, reconstruction and technical re-equipment of the industrial complex for the production of full-cycle medicines on the basis of the Federal State Unitary Enterprise “Moscow Endocrine Plant”, Lefortovo Branch, city of Moscow.
The project is implemented in accordance with the goals set by the State Program of the Russian Federation “Development of the Pharmaceutical and Medical Industry”, and the following tasks are solved:
- ensuring national security in the field of drug supply to citizens of the Russian Federation with domestic centrally acting analgesics and other drugs included in the vital and essential medicines list;
- creating modern laboratories for the development of new medicines, substances and reference materials;
- improving the quality of manufactured products and reducing the cost of manufactured drugs;
- creating a laboratory and production complex for the development, production and certification of reference (analytical) materials of chemical and biological compounds and their impurities.
At the first stage of the project implementation, the Scientific and Laboratory Complex is reconstructed and technically re-equipped, which is financed from the federal budget and the Enterprise’s own funds.
As part of the renovated complex, it is planned to establish:
- a site for the development of production processes of the active pharmaceutical ingridients obtained by chemical synthesis from plant and animal raw materials;
- analytical laboratories and laboratories for the development and transfer of advanced technologies for the production of finished medicines;
- a pilot production site for the production of medicines, including for conducting clinical trials;
- microbiological and chemical laboratories for quality control of raw materials and products;
- a full-scale site for the development and production of reference materials.
The facility with a total area of 6,200 m² will be equipped with modern analytical and pilot equipment, including domestically produced. More 250 jobs are planned to be created. The total cost of the project is about 900 million rubles, about 402 million rubles of FSUE “Endopharm”’s own funds were invested in the construction of the Scientific and Laboratory Complex.
“The main construction and installation works have already been completed. The construction is at the final stage. We are now preparing for commissioning.
Unhindered passage to the Lefortovo Branch is organized, sidewalks are paved and lighting is installed, the territory is landscaped, - Dmitry Averyanov, Deputy General Director, Director of the Lefortovo Branch of FSUE “Endopharm”.
In June 2022, the Center for the Development of Biotechnological and Innovative Medicines on the basis of the Lefortovo Branch of FSUE “Endopharm” was put into operation. The tasks of the Center are development and improvement of production technologies for more than 60 active pharmaceutical ingridients, as well as high-tech medicines.
In 2023, at the next stage of the investment project implementation in the Lefortovo Branch, a high-tech production facility will be commissioned. The facility will be capable to produce, per year, 73 million medicines in ampoules and vials, including lyophilized drugs and emulsions, about 1 billion tablets and capsules, 10 million medicines in the form of sprays, and 33 million transdermal patches and transmucosal films based on the Enterprise’s own developments.
Comment type is not specified in the component properties.